12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Emerging therapeutics for Alzheimer's disease: an avenue of hope.

      CNS Spectrums
      Alzheimer Disease, drug therapy, etiology, pathology, Antioxidants, therapeutic use, Brain, drug effects, Cardiovascular Agents, Chelating Agents, Cholinesterase Inhibitors, Clinical Trials as Topic, Drug Therapy, Combination, Humans, N-Methylaspartate, antagonists & inhibitors, Nootropic Agents, Vaccines

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Emerging therapies for Alzheimer's disease offer hope to patients and their caregivers. Future treatments will probably include combination approaches with agents that modify amyloid processing, deposition, and clearance. One example, the AD vaccine, reduced amyloid burden and changed behavior in animal models of AD, but the human trial was halted when several subjects developed brain inflammation. Anti-inflammatory agents have epidemiologic support, but clinical trials have been disappointing, possibly related to inadequate study with anti-inflammatory agents that modify amyloid processing. Agents that target known cardiovascular risk factors, such as hypercholesterolemia, hypertension, and insulin resistance, have epidemiologic, preclinical, and clinical evidence to warrant further investigation. Heavy metal chelators, antioxidants, neurotrophic factors, glutaminergic modulators, and agents that modify hyperphosphorylation of Tau are other approaches in research and development.

          Related collections

          Author and article information

          Comments

          Comment on this article